On Wednesday, TransMedics Group got an upgrade to its Relative Strength (RS) Rating, from 61 to 74.
Can You Really Time The Stock Market?
IBD's proprietary RS Rating measures technical performance by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database.
Decades of market research reveals that the top-performing stocks tend to have an 80 or higher RS Rating in the early stages of their moves. See if TransMedics Group can continue to show renewed price strength and hit that benchmark.
TransMedics Group is building a consolidation with a 145.50 buy point. See if it can break out in volume at least 40% above average.
Earnings growth rose in the company's most recent report from 100% to 163%, but sales fell from 48% to 38%.
TransMedics Group earns the No. 5 rank among its peers in the Medical-Products industry group. Insulet is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Rising Relative Strength?
